AbbVie (NYSE:ABBV) Shares Climb 1.3% – Should You Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price was up 1.3% during mid-day trading on Friday. The stock traded as high as $264.06 and last traded at $263.2670. Approximately 5,540,598 shares were traded during mid-day trading, a decline of 14% from the average session volume of 6,439,068 shares. The stock had previously closed at $259.93.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approval expands AbbVie’s neuroscience portfolio. The FDA approved Juvmo for Parkinson’s disease, with a commercial launch targeted for October 2026. The new product could diversify growth beyond immunology and help strengthen AbbVie’s neuroscience franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: RINVOQ showed continued efficacy in vitiligo. Phase 3 Viti-Up-1 and Viti-Up-2 results showed that facial and total-body repigmentation continued to improve through week 76. Responses were also numerically higher when RINVOQ was combined with narrowband UV-B phototherapy, supporting the drug’s potential for broader dermatology growth. AbbVie Presents Long-Term RINVOQ Data
• Positive Sentiment: Pipeline activity remains active. AbbVie provided an update on an ongoing study evaluating Venetoclax in acute myeloid leukemia, while recent dermatology data and the Juvmo approval reinforce investor expectations for continued product-led growth. AbbVie’s Venetoclax AML Study Update
• Neutral Sentiment: Third-quarter results are approaching. AbbVie will report third-quarter 2026 results before the market opens on October 30, giving investors a near-term catalyst to assess Juvmo expectations, RINVOQ and Skyrizi momentum, and overall earnings guidance. AbbVie Third-Quarter 2026 Earnings Conference Call
• Negative Sentiment: Valuation and legacy-product pressure remain risks. AbbVie’s strong recent performance has raised concerns about whether its valuation fully reflects future cash-flow growth. Humira erosion, competitive pressure, and the need for newer products such as Juvmo to scale commercially could limit further upside.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research reports. Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Oppenheimer increased their price objective on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Finally, Rothschild & Co Redburn boosted their price objective on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $272.66.

AbbVie Price Performance

The firm’s 50 day moving average is $257.79 and its 200 day moving average is $234.39. The company has a market capitalization of $465.14 billion, a PE ratio of 74.37, a P/E/G ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Hedge Funds Weigh In On AbbVie

Several hedge funds have recently made changes to their positions in the business. GoalVest Advisory LLC lifted its stake in AbbVie by 0.8% in the third quarter. GoalVest Advisory LLC now owns 6,630 shares of the company’s stock worth $1,734,000 after acquiring an additional 53 shares during the period. Private Client Services LLC increased its position in AbbVie by 2.5% during the 3rd quarter. Private Client Services LLC now owns 3,670 shares of the company’s stock valued at $960,000 after purchasing an additional 88 shares during the period. Global Wealth Strategies & Associates raised its holdings in AbbVie by 11.8% in the 3rd quarter. Global Wealth Strategies & Associates now owns 1,486 shares of the company’s stock worth $389,000 after purchasing an additional 157 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of AbbVie by 4.4% in the 3rd quarter. Versant Capital Management Inc now owns 7,204 shares of the company’s stock worth $1,884,000 after purchasing an additional 305 shares during the period. Finally, First Financial Bank Trust Division boosted its stake in shares of AbbVie by 3.3% during the 3rd quarter. First Financial Bank Trust Division now owns 26,729 shares of the company’s stock valued at $6,992,000 after purchasing an additional 854 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.